Fungal Infections in Transplant and Oncology Patients

Person, Anna K.; Kontoyiannis, Dimitrios P.; Alexander, Barbara D.

doi:10.1016/j.hoc.2010.11.013

Cited by 30 publications

(10 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 Despite advances in technology and therapy, invasive fungal infections are still associated with significantly high morbidity and mortality. 3 Among SOT recipients, Candida and Aspergillus pathogens continue to be most often implicated as the cause of infections. 1 However, Aspergillus species and other filamentous molds, such as Fusarium, Scedosporium, and the Zygomycetes, are more commonly associated with invasive fungal infections in HSCT recipients.…”

Section: Ce Updatementioning

confidence: 99%

(1–3)-β-D-Glucan Assay: A Review of its Laboratory and Clinical Application

Wright

Overman

Ribes

2011

Lab Med

View full text Add to dashboard Cite

A new fungal surrogate marker, (1-3)-β-D glucan, offers a noninvasive method for the potential surveillance and diagnosis of invasive fungal infections. Invasive fungal infections have long been associated with significantly high morbidity and mortality on hematology-oncology wards and recipients of either solid-organ or hematopoietic stem cell transplantation. The diagnoses of invasive fungal infections have historically been made difficult by the need for invasive methods.(1-3)-β-D-glucan testing requires a minimally invasive sample that can be used to aid in the diagnosis of an invasive fungal infection as well as monitor the response to treatment. One disadvantage of (1-3)-β-D-glucan testing is that a positive test alone lacks sufficient sensitivity and specificity for a definitive diagnosis. While formal guidelines for the use of (1-3)-β-D-glucan testing are lacking, this chromogenic assay provides a new opportunity for testing at-risk populations. A review and recommendation for its laboratory and clinical application are provided. Glossary(1-3)-β-D-glucan: A polysaccharide component of the cell wall of most fungi pyrogen test. An assay used to determine if a pharmaceutical or medical device intended for human use will stimulate fever.Keywords: (1-3)-β-D glucan, beta glucan assay, invasive fungal infections After reading this article, readers should be able to discuss what (1-3)-β-D glucans are, how they are detected in clinical biological samples, the evidence to support laboratory testing and monitoring, the limitations of testing, and the appropriate clinical setting for testing.Microbiology 71103 questions and corresponding answer form are located after this CE Update on page 686.

show abstract

Section: Ce Updatementioning

confidence: 99%

(1–3)-β-D-Glucan Assay: A Review of its Laboratory and Clinical Application

Wright

Overman

Ribes

2011

Lab Med

View full text Add to dashboard Cite

show abstract

“…Se han producido avances en el diagnóstico de estas infecciones [5,6], a pesar de su baja prevalencia en la práctica hospitalaria, tienen un incremento en la tasa de morbi-mortalidad de pacientes que su sistema inmune no responde adecuadamente [7]. La infección por Candida spp.…”

Section: Introductionunclassified

Costo Efectividad de Posaconazol versus Fluconazol/Itraconazol en el Tratamiento Profiláctico de las Infecciones Fúngicas Invasivas en México

Rely¹,

Alexandre

Salinas-Escudero

2011

Value in Health

View full text Add to dashboard Cite

show abstract

“…T he shift to non-albicans Candida species over the past 2 decades is a worrisome trend, as these species frequently exhibit decreased susceptibility to azoles, justifying the use of echinocandins in first-line empirical treatment of invasive candidiasis (1)(2)(3). Micafungin is a well-tolerated echinocandin that met noninferiority criteria in two randomized trials in comparison with liposomal amphotericin B (4) and caspofungin (5).…”

mentioning

confidence: 99%

Efficacy and Tolerability of Micafungin Monotherapy for Candidemia and Deep-Seated Candidiasis in Adults with Cancer

Farmakiotis

Tarrand

Kontoyiannis

2014

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

The response rate among 58 patients with cancer and candidemia or deep-seated candidiasis treated with micafungin monotherapy was 81%. Intensive care unit (ICU) stay, concomitant nonfungal infections, and acute kidney injury were significantly associated with the 30-day crude mortality rate. Severe neutropenia was an independent predictor of micafungin failure. The efficacy and safety of micafungin in cancer patients with invasive candidiasis were comparable to those reported for patients without malignancy and for cancer patients treated with caspofungin.

show abstract

Fungal Infections in Transplant and Oncology Patients

Cited by 30 publications

References 118 publications

(1–3)-β-D-Glucan Assay: A Review of its Laboratory and Clinical Application

(1–3)-β-D-Glucan Assay: A Review of its Laboratory and Clinical Application

Costo Efectividad de Posaconazol versus Fluconazol/Itraconazol en el Tratamiento Profiláctico de las Infecciones Fúngicas Invasivas en México

Efficacy and Tolerability of Micafungin Monotherapy for Candidemia and Deep-Seated Candidiasis in Adults with Cancer

Contact Info

Product

Resources

About